isoniazid and u 100480
isoniazid has been researched along with u 100480 in 10 studies
Research
Studies (10)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Barbachyn, MR; Brickner, SJ; Cynamon, MH; Ford, CW; Glickman, SE; Grega, KC; Hendges, SK; Hutchinson, DK; Kilburn, JO; Klemens, SP; Toops, DS; Zurenko, GE | 1 |
| Artico, M; La Colla, P; Loddo, R; Mai, A; Sbardella, G; Setzu, MG | 1 |
| Barbachyn, MR; Brickner, SJ; Hutchinson, DK; Manninen, PR | 1 |
| Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N | 1 |
| Biava, M; Cocozza, M; Consalvi, S; Poce, G | 1 |
| Fu, L; Huang, H; Li, G; Li, Y; Liu, Y; Lu, H; Lu, Y; Ma, C; Sheng, L; Wang, B; Zhang, B; Zhang, D; Zhao, H | 1 |
| Castagnolo, D; Denny, WA; Dos Santos, JL; Fernandes, GFS; Thompson, AM | 1 |
| Alffenaar, JW; de Neeling, H; Simons, S; van de Kasteele, PJ; van der Laan, T; van der Werf, TS; van Soolingen, D | 1 |
| Amoabeng, O; Andries, K; Mdluli, KE; Minkowski, A; Nuermberger, EL; Peloquin, CA; Taylor, D; Wallis, RS; Williams, K | 1 |
| Fattorini, L; Giannoni, F; Iacobino, A; Pardini, M; Piccaro, G | 1 |
Reviews
4 review(s) available for isoniazid and u 100480
| Article | Year |
|---|---|
Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Positive Bacterial Infections; Humans; Linezolid; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones | 2008 |
Tuberculosis: the drug development pipeline at a glance.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis | 2012 |
SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Tuberculosis Drug Discovery: Challenges and New Horizons.
Topics: Antitubercular Agents; COVID-19 Drug Treatment; Drug Discovery; Humans; Mycobacterium tuberculosis; Tuberculosis | 2022 |
Other Studies
6 other study(ies) available for isoniazid and u 100480
| Article | Year |
|---|---|
Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microbial Sensitivity Tests; Mycobacterium avium; Mycobacterium tuberculosis; Oxazoles; Rats | 1996 |
Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480.
Topics: Anti-Bacterial Agents; Cell Line; Humans; Mycobacterium avium; Mycobacterium tuberculosis; Oxazolidinones | 2004 |
Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis.
Topics: Animals; Chlorocebus aethiops; Drug Design; Female; Hep G2 Cells; Humans; Mice; Microbial Sensitivity Tests; Molecular Conformation; Mycobacterium tuberculosis; Oxazolidinones; Safety; Tuberculosis, Multidrug-Resistant; Vero Cells | 2020 |
Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.
Topics: Acetamides; Antitubercular Agents; Ethambutol; Isoniazid; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazolidinones; Rifampin; Streptomycin; Tuberculosis, Multidrug-Resistant | 2011 |
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2012 |
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
Topics: Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans; Hydrogen-Ion Concentration; Hypoxia; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis | 2019 |